The impact of qualitative [18F]FDG PET/CT in predicting clinical outcomes of post-surgical differentiated thyroid cancer patients with elevated thyroglobulin and negative radioiodine whole-body scan Authors: Le Ngoc Ha, Nguyen Thi Phuong, Mai Hong Son Published: 2024 ABSTRACT AbstractBackground[18F]FDG PET/CT has been widely used as a diagnostic tool in detection and localization of recurrent non-avid radioiodine lesions in post-operative differentiated thyroid cancer (DTC) patients with elevated serum thyroglobulin but negative radioiodine whole-body scan (TENIS) syndrome. The aim of our study was to evaluate the role of [18F]FDG PET/CT in prediction on outcomes of these DTC patients.MethodsPost-operative DTC patients with TENIS syndrome were collected in the department of nuclear medicine, Hospital 108 from 2019 to 2023. Patients underwent [18F]FDG PET/CT with standard protocol following EANM guideline for tumor imaging version 2.0. The qualitative [18F]FDG PET/CT imaging characteristics were classified into three categories: (i) negative [18F]FDG PET/CT, (ii) minimal [18F]FDG PET/CT volume of lesions, (iii) extensive [18F]FDG PET/CT volume of lesions. Progression-free survival (PFS) and overall survival (OS) were the end point of the study. The prognosis of qualitative [18F]FDG PET/CT in predicting PFS and OS was illustrated by Kaplan–Meier survival analysis. The independent factors predicting PFS and OS were determined by univariate and multivariate analysis using logistic regression.ResultsThere were 164 consecutive patients, 51.2% female and 48.8% female. The most common histopathological type was papillary accounting for 91.5%. The median time of follow-up was 33.3 months, (range 6.57 – 82.5). There was 70 (36.6%) progressions and 12 (7.35%) deaths. Negative [18F]FDG PET/CT uptake patients had median PFS with median 57.1 months which was higher than that of minimal category (46.2 months), and extensive category (37.6 months) (p < 0,001). 1-year OS and 5-year OS in extensive PET/CT category was 97.8% and 86.2% respectively which were significantly lower than that of negative and minimal categories (p = 0.053). In multivariate analysis, age at the time of diagnosis, pulmonary, bone metastases and extensive [18F]FDG PET/CT volume of lesions were the independent factor predicting PFS. Bone metastasis was only the factor could predict OS in multivariate analysis.ConclusionsThe minimal and negative [18F]FDG PET/CT categories had better prognosis than extensive category in PFS and OS. Extensive [18F]FDG PET/CT category was an independent factor for predicting PFS. Bone metastasis was only the independent factor that could predict both PFS and OS.Keywords: [18F]FDG PET/CT, Qualitative, Prognosis, PFS, OS, TENIS, Differentiated thyroid cancer Introduction Thyroid cancer is one of the most common malignancy among the endocrine tumors worldwide. Differentiated thyroid cancer (DTC) accounts for 90% of thyroid carcinoma presenting with favorable prognosis [1]. However, there are 10—27% of post-treatment patients may lost the ability of radioiodine uptake with high thyroglobulin (Tg) level (TENIS syndrome). In this scenario, neck ultrasound, and computed tomography (CT) are widely used for follow-up and diagnosis of recurrence and metatastases [2, 3]. However, in cases where recurrent and/or metastatic lesions cannot be detected by conventional imaging methods, [18F]FDG PET/CT ([18F]Fluorodeoxyglucose Positron Emission Tomography/ Computed Tomography) is preferred. [18F]FDG PET/CT has emerged as a more valuable diagnostic tool than ultrasound and/or CT for detecting and localizing recurrence and metastases in TENIS syndrome, with high sensitivity and specificity [4–6]. Previous studies have shown that [18F]FDG PET/CT is an important diagnostic tool in cases where conventional imaging methods fail to detect recurrent or metastatic lesions [7, 8]. Moreover, the crucial role of [18F]FDG PET/CT was well established in DTC patients with high risk according to ATA (American Thyroid Association) classification, in patients with elevated Tg levels, and even in those with low Tg levels [9–11]. In addition, metabolic features of [18F]FDG PET/CT may predict prognosis and outcome [12–14]. A recent systematic review by Wang H et al. indicated that several semi-quantitative parameters, including standard uptake values (SUVs) such as SUVmax, SUVmean, and SUVpeak, as well as volume-based PET parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), either individually or in conjunction with other variables, may serve as prognostic markers for predicting poor outcomes in TENIS syndrome. [15]. However, using these semi-quantitative PET parameters in clinical practice still poses challenges due to the methodological measurement standardization, reproducible issues and technical variations arising from PET scanner used and PET center’s features [16]. In clinical context, location, and the extent of metastatic/recurrent [18F]FDG-avid lesions on PET/CT imaging play an important role for clinical decision making for management of DTC patients [17]. Therefore, qualitative PET/CT presenting the level of extent or absence of [18F]FDG-avid lesions in TENIS syndrome, tends to be more feasible than semi-quantitative parameters [18]. However, there are limited publications determining prognosis of qualitative [18F]FDG PET/CT in this patient cohort. The purpose of our study is to evaluate the impact of qualitative [18F]FDG PET/CT imaging on the predicting outcomes for DTC patients with TENIS syndrome. Methods Patient’s population We recruited 164 post-operative DTC consecutive patients with TENIS syndrome who underwent [18F]FDG PET/CT from October 2019 to December 2023 in department of nuclear medicine, Hospital 108, Hanoi, Vietnam. The inclusion criteria were: (i) DTC patients have negative 131I-WBS prior [18F]FDG PET/CT scan 1 – 3 months; (ii) serum Tg ≥ 10 ng/mL at the time of the PET/CT scan; (iii) negative Tg-antibodies at the time of PET/CT scan; (iv) patients have medical records and could be followed-up. All the procedures were standard of care, the committee agreed to waive the need for written informed consent. The present study protocol was reviewed and approved by the Tumor Board of Hospital 108 (approval No. 338/QĐ-VNC). [18F]FDG PET/CT Procedures A whole-body [18F]FDG PET/CT examination was conducted using GE Discovery 710 scanner (GE Healthcare, Milwaukee, WI, USA), following the guidelines of the European Association of Nuclear Medicine (EANM) version 2.0 [19]. To prepare the patients, serum glucose levels were assessed to rule out hyperglycemia. Each patient fasted at least 6-h before PET/CT scan with a blood glucose level below 200 mg/dL. Subsequently, patients rested in the waiting room before receiving an intravenous injection of 2.5 MBq/kg body weight (± 10%) of [18F]FDG. PET/CT imaging was conducted approximately after the injection for 60 min. PET images were acquired in a three-dimensional mode, 6–8 bed positions (1.5 min per bed position), 50 cm transaxial field of view (FOV). Reconstruction algorithm used is time of flight (TOF) + point spread funtion (PSF) with the use of ordered-subsets implementations (OSEM) with 4 iterations, 20 subsets, Gaussian post-filtering at 4-6 mm, and matrix size of 256 × 256. The CT scan parameters were set at 120 kVp, 100 mA, with helical thickness of 3.75 mm and rotation speed of 0.5 s/rotation. PET images were reconstructed utilizing iterative algorithm with attenuation correction based on CT. Following whole body PET/CT imaging, a dedicated head and neck protocol was implemented. The dedicated protocol was performed from the cranial top to the thoracic inlet, with the patients positioned arm-down. PET images were acquired in a three-dimensional mode, two bed positions (for 1.5 min per bed position), 70 cm transaxial field of view (FOV), iterative reconstruction, 20 subsets/2 iterations and a matrix size of 256 × 256. The CT ‘s parameters were set at 120 kVp, 100 mA, helical thickness of 1.25 mm, matrix size of 512 × 512, and 0.5 s/rotation. [18F]FDG PET/CT images were displayed in the trans-axial, sagittal, and coronal planes using the PET Volume Viewer, GE workstation (version 4.7, GE Healthcare). The qualitative evaluation was performed on whole-body imaging, with a dedicated head and neck PET/CT imaging used to assist in detecting small lesions. Histopathological type of DTC was divided into papillary, follicular, aggressive variant and papillary/follicular types [20]. The stage at the time of diagnosis of DTC was followed by TNM (Tumor Node Metastasis) staging system, AJCC (American Joint Committee on Cancer) 8th edition [21]. TSH (Thyroid Stimulating Hormone), Tg, and anti-Tg serum concentration tests were conducted at the Department of Biochemistry, 108 Military Central Hospital, using the Elecsys analyzer (Roche, Switzerland) and employing the electrochemiluminescence immunoassay method. In our study, stimulated Tg was measured within 3 months before the PET/CT scan, and all patients received only suppressed hormone therapy during this period. The stimulated Tg was assessed following a 4-week withdraw of thyroid hormone with a TSH level of ≥ 30 µIU/ml. Qualitative [18F]FDG PET/CT assessment The characteristic imaging of [18F]FDG PET/CT was divided into three groups: negative, minimal and extensive [18F]FDG PET/CT volume of lesions. Qualitative assessment of lesions was considered negative when there was no evidence of focal FDG uptake or abnormalities on CT. Minimal [18F]FDG PET/CT volume of lesions was defined as either a single lesion or multiple lesions in a single organ, each with a longest diameter less than 1 cm without threatening disease progression. Extensive [18F]FDG PET/CT volume of lesions was characterized by a single lesion in a single organ with the longest diameter exceeding 1 cm, or single lesions/multiple lesions in multiple organs with any size. The interpretation of [18F]FDG PET/CT was conducted independently by two experienced nuclear medicine physicians with comprehensive knowledge of the patient's clinical history. Any disagreements were resolved through consensus by another expert. Follow-up and treatment The strategy of treatment was decided by thyroid carcinoma board of Hospital 108. Negative [18F]FDG PET/CT cases were followed-up every six months by neck ultrasound and serum Tg. The patients with minimal [18F]FDG PET/CT volume of lesions were placed on ‘’wait and watch’’ with active surveillance. Extensive positive PET volume of lesions was considered to treatment with surgery, radiation therapy or systemic therapy based on clinical scenario of each patient. All patients were followed-up for at least 12 months after the PET scan. The study's endpoints included PFS and OS. Disease progression was characterized by the emergence of new metastases in accordance with ultrasound, CT or [18F]FDG PET/CT. Disease progression was evaluated according to the RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) criteria and/or PERCIST 1.0 (Positron Emission Tomography Response Criteria in Solid Tumors) criteria. In the event of detected disease progression during patient monitoring, the thyroid cancer board assembled to establish a consensus on the most suitable treatment strategy. The study's endpoint included PFS, calculated from the time of study enrollment to either disease progression, and OS was determined from the time of study enrollment to the occurrence of death. The confirmation of malignancy was performed by fine needed biopsy or histopathology. Mortality and its causes were determined by telephone interviews with family members and/or medical records of the hospital. Statistical analysis The statistical analysis was performed by commercial software (SPSS Inc, Chicago, IL). Categorical values were compared utilizing the Chi-squared test or Fisher’s exact test. Continuous variables following normal distribution were compared with paired t-test or repeated measure ANOVA and for variables not following a normal distribution with Wilcoxon signed-rank test or Friedman test. Categorical variables were evaluated by χ2 analysis. PFS and OS, were measured by the time between the date of PET scan and date of recurrence, death, or last follow-up, is the primary end point of this study. Univariate and multivariate analysis were performed by Cox proportional hazards model. Survival curves were generated using Kaplan–Meier estimates, and the log-rank test for PFS differences was used to assess significance. P < 0.05 was considered to indicate a significant difference. Results The clinical features of patients with TENIS syndrome are listed in Table 1. The classic papillary carcinoma was the most prevalent, accounting for with 150 (91.5%) cases, followed by follicular carcinoma with 11 (6.7%) cases, and aggressive variants 3 (1.8%) cases. Regarding the ATA risk classification before the first 131I treatment, there were 50 (30.5%) patients in the low-risk group, 66 (40.2%) in the intermediate—risk group and 48 (29.2%) in the high-risk group. The median time of follow-up was 33 months (range 3.57 – 88.5 months). The median PFS and OS were 19 months (range 1–132 months) and 46 months (range 3–145 months) respectively. The progression of disease occurred in 60 (36.6%) patients and there were 12 (7.3%) deaths. Table 1General characteristics of DTC patients with TENIS syndrome (n = 164)CharacteristicsPatient’s number (n = 164)Percentage (%)Age (mean, year)50.1 ± 14Age at the time of diagnosis (year) < 5510161.1 ≥ 556338.4GenderMale8051.2Female8448.8Male/female ratio1/1.05Histopathological typePapillary15091.5Follicular/ Aggressive variant148.5T stageT1-210061T3-45030.5Tx148.5N stageN03521.3N112978.7M stageM014085.4M12414.6ATA—risk classLow5030.5Intermediate6640.2High4829.3Stimulated Tg before PET/CT scan (median, range, ng/ml)139 (10 – 5982)Number of 131I therapy course(s) before PET/CT scan (mean)2.83 ± 1.355Cumulative RAI activities administrated (mean, mCi)385.6 ± 215.3Time of follow-up (median, range, months) 33.3 (3.57 – 82.5)Progressive disease6036.6Death127.2 General characteristics of DTC patients with TENIS syndrome (n = 164) The extent of qualitative [18F]FDG PET/CT imaging is presented in Table 2. The negative, minimal and extensive [18F]FDG PET/CT volume of lesions were observed in 54/164 (32.9%), 21/164 (12.8%) and 89/164 patients (54.3%) respectively. In the minimal group, there were two of 21 patients (9.5%) had multiple lesions in a single organ. Lesions detected by [18F]FDG PET/CT were in various locations as follow: 17 (10.4%) in thyroid bed (Fig. 1A), 86 (52.4%) in cervical lymph nodes, 28 (17.1%) in pulmonary metastases, 11 (6.7%) in bone metastases (Fig. 1B), 23 (14%) in mediastinal metastases, and 7 (4.3%) in other soft tissues. Table 2Characteristics of qualitative [18F]FDG PET/CT imagingCharacteristicsNumber(n = 164)Percentage(%)[18F]FDG PET/CT lesions volumeNegative [18F]FDG PET/CT5432.9Minimal [18F]FDG PET/CT2112.8Extensive 18F-FDG PET/CT8954.3Location of the lesion(s)Thyroid beds1710.4Cervical lymph node8652.4Pulmonary metastases2817.1Bone metastases116.7Mediastinal lymph node2314Other soft tissue organ74.3 Characteristics of qualitative [18F]FDG PET/CT imaging A Minimal [18F]FDG PET/CT volume of a lesion with mild focal uptake in the thyroid bed (arrow shown on PET, CT, PET/CT, and multi-projection image (MIP)). B Extensive [.18F]FDG PET/CT volume of lesions indicating thyroid bed recurrence, as well as lung and bone metastases (arrows) A significant relationship between clinical features and category of 18F-FDG volume lesions was depicted in Table 3. The predictive probability of PFS based on 18F-FDG volume lesions is illustrated in Fig. 2. The median PFS of patients with negative, minimal, and extensive PET/CT patients was 57.1, 46.2 and 37.6 months respectively, with the significant difference (p < 0.001). The percentage of PFS in the extensive [18F]FDG PET/CT group decreased from 85.1% in the 1st year to 26.4% in the 5th year. Univariate analysis identified several independent factors predicting PFS including age, T stage and M stage, histopathological types, cumulative RAI (radioactive-iodine) activities administrated, stimulated Tg, lung, and bone metastases, and extensive [18F]FDG PET/CT volume. Multivariate analysis further confirmed age at the time of diagnosis, presence of lung, bone metastases, and extensive 18F-FDG volume of lesions as the independent unfavorable factors for disease progression (Table 4). Table 3Relationship between clinical features and the qualitative of [18F]FDG PET/CTClinical features[18F]FDG PET/CT volume of lesions(n = 164)p (χ2)Negative (n, %)Minimal (n, %)Extensive (n, %)Age at the time of diagnosis < 55 years47 (46.5%)17 (16.8%)37 (36.6%) < 0.001*(33.182) ≥ 55 years7 (11.1%)4 (6.3%)52 (82.5%)GenderMale19 (23.8%)8 (10%)53 (66.3%)0.011* (9.086)Female35 (41.7%)13 (15.5%)36 (42.9%)Histopathological typePapillary54 (36%)20 (13.3%)76 (50.7%)0.008* (9.62)Follicular/Aggressive variant01 (7.1%)13 (92.9%)Distant metastasisM051 (36.4%)19 (13.6%)70 (50%)0.027*(7.213)M13 (12.5%)2 (8.3%)19 (79.2%)Cumulative RAI activities administrated (mCi) ≤ 600 mCi52 (35.6%)20 (13.7%)74 (50.7%)0.032* (6.9) > 600 mCi2 (11.1%)1 (5.6%)15 (83.3%)Stimulated Tg (ng/mL) ≤ 13940 (48.2%)15 (18.1%)28 (33.7%) < 0.001* (33.96) > 13914 (14.3%)6 (7.4%)61 (75.3%)*Significant difference Relationship between clinical features and the qualitative of [18F]FDG PET/CT < 0.001* (33.182) 0.027* (7.213) *Significant difference Kaplan–Meier progression-free survival curves for different patient’s group based on the pattern of [18F]FDG avid lesions Table 4Univariate and multivariate analysis for PFSFactorsUnivariate analysisMultivariate analysisHR95% ClpHR95% ClpAge at the time of diagnosis < 55 years11 ≥ 55 years6.933.85 – 12.49 < 0.001*2.51.2 – 5.30.02*GenderFemale1---Male1.340.78 – 2.30.294---T stageT1- 211T3- 41.771.02 – 3.070.042*1.30.7 – 2.40.4Tx1.820.8 – 4.150.1561.40.6 – 3.60.48N stageN01---N10.730.4 – 1.330.296---M stageM011M12.351.33 – 4.130.003*0.80.4 – 1.70.6Histopathologial typePapillary11Follicular / Aggressive variant5.933.1 – 11.5 < 0.001*1.30.6 – 2.90.45Cumulative RAI activities administrated ≤ 600 mCi11 > 600 mCi1.991.03 – 3.850.04*1.40.6 – 3.10.43Stimutalated Tg(ng/mL) ≤ 13911 > 1392.461.36 – 4.450.003*0.90.6 – 1.70.71Thyroid bed recurrencesNo1---Yes1.880.99 – 3.560.053---Cervical lymph node recurrencesNo1---Yes1.660.96 – 2.850.067---Pulmonary metastasesNo11Yes6.824.08 – 11.42 < 0.001*4.12.1 – 8.1 < 0.001*Bone metastasesNo11Yes6.043.01 – 12.1 < 0.001*4.561.8 – 11.40.001*[18F]FDG PET/CT volume of lesionsNegative11Minimal4.340.79 – 23.70.093.70.7 – 20.30.14Extensive14.53.52 – 59.4 < 0.001*4.61.02 – 20.50.046* Univariate and multivariate analysis for PFS The 1-year OS and 5-year OS in DTC patients with extensive [18F]FDG PET/CT volume were 97.8% and 86.2% respectively, showing lower tendency compared to those of negative PET and minimal [18F]FDG PET/CT volume (p = 0.053, Fig. 3.). In univariate analysis, significant prognostic factors for predicting OS included patient’s age > 55, follicular and aggressive type, and bone metastases. However, in multivariate analysis, the presence of bone metastases was the independent prognostic indicator for the worse survival in DTC patients with TENIS syndrome (Table 5). Kaplan–Meier overall survival curves for different patient’s group based on the pattern of [18F]FDG avid lesions Table 5Univariate and multivariate analysis for OSFactorsUnivariate AnalysisMultivariate AnalysisHR95% ClpHR95% ClpAge at the time of diagnosis < 55 years11 ≥ 55 years5.951.28 – 27.70.023*3.80.7 – 200.11GenderFemale1Male0.990.31 – 3.180.982---Stage T at diagnosisT1- 21T3- 41.180.27 – 5.090.827---Tx3.810.89 – 16.270.071---Stage N at diagnosisN01N10.550.16 – 1.880.342---Stage M at diagnosisM01M12.40.7 – 8.320.166---Histopathological typePapillary11Folicular/ Aggressive variant4.51.25 – 16.50.021*1.40.3 – 6.30.63Cumulative RAI activities administrated ≤ 600 mCi1 > 600 mCi5.241.57 – 17.550.127---Stimulated Tg ≤ 139 ng/ml1 > 139 ng/ml520.29 – 97240.139---Pulmonary metastasesNo1Yes3.10.94 – 10.280.064---Bone metastasesNo11Yes7.432.22 – 24.940.001*4.241.13 – 15.90.032*[18F]FDG PET/CT volume of lesionsNegative1Minimal1.030 – 908240.997---Extensive44.20.06 – 320090.259---HR Hazard ratio, CI Confidence interval, N Number*significant difference Univariate and multivariate analysis for OS HR Hazard ratio, CI Confidence interval, N Number *significant difference Discussions In this study, we demonstrated the various patterns of [18F]FDG PET/CT volume of lesions in clinical decision-making and their prognostic value in predicting outcomes for patients with TENIS syndrome. The follow -up and treatment strategies for DTC patients was identified by age, gender, pTNM and post-operative risk factors based on American thyroid association guidelines 2015 [22]. In TENIS syndrome, localization, diameters, volume of recurrence/metastases detected by [18F]FDG PET/CT play a key role in selecting treatment strategies [22, 23]. Follow-up, local, or systemic therapy were determined depending on the volume of [18F]FDG PET/CT lesions and clinical scenarios. In our study, patients with negative [18F]FDG PET/CT were followed up and treated with TSH suppression therapy. Those with minimal [18F]FDG PET/CT lesion volumes were recommended for a "wait and watch" strategy involving active surveillance. They were considered on a case-by-case basis for radiation, surgery, or systemic therapy if progression of disease occurred. Meanwhile, patients with extensive lesions, depending on their location, were considered for local and/or systemic therapy. Upon detection of a lesion on PET/CT, the thyroid cancer board convened to determine the optimal treatment strategy, which may include the following options: (1) surgery and localized radiation therapy for localized lesions, (2) chemotherapy and targeted therapy for lesions with multiple rapidly advancing sites, (3) treatment with experienced dosage of 131I or TSH suppression therapy and monitoring for small, slowly progressing lesions [22, 24, 25]. On the other hand, limited number of studies have explored the clinical ramifications of [18F]FDG PET/CT on managing patients with DTC [26, 27]. Larg et al. revealed that [18F]FDG PET/CT could influence clinical decision-making for DTC patients with elevated Tg levels and negative 131I WBS, resulting in a treatment strategy alteration in 33.5% (58/173) of cases [28]. [18F]FDG PET/CT serves as a prognostic marker in predicting outcomes of patients with TENIS syndrome [17]. Our study results demonstrated that patients with negative [18F]FDG PET/CT results had a favourable prognosis without progression disease within two years follow-up. Ranade et al. concluded that in DTC patients with Tg elevation, a negative [18F]FDG PET could be considered a valuable sign for predicting PFS over a three year follow-up period [29]. Although there was a significant difference between the PFS of negative and minimal [18F]FDG PET groups, no significant difference was observed in OS. This suggests that the strategy of follow-up and "wait and watch" with active surveillance, combined with suppressed hormonal therapy, may offer a favorable prognosis for patients in both negative and minimal [18F]FDG PET groups. Our study illustrated that patients with extensive [18F]FDG PET findings, characterized by large and disseminate lesions, had lower PFS and OS rates compared to those with negative and minimal [18F]FDG PET results. The number and location of lesions on [18F]FDG PET/CT scans were associated with survival outcomes [30]. In another study, the number of lesions was classified into four categories: negative, 1–2, 3–10 and more than 10 lesions,OS decreased as the number of FDG avid lesions increased. In univariate analysis, patients with cervical lymph nodes involvement had the best survival outcomes, while those with supraclavicular and mediastinal lymp nodes had slightly worse outcomes. Patients with distant organ metastases had the poorest OS [31]. In addition to extensive volume of lesions on [18F]FDG PET, age, T stage, M stage, follicular histopathological type, cumulative dose of 131I, elevated stimulate Tg and the presence of lung and bone metastases were the predictors of poor PFS after PET/CT scan in this study. Age, the presence of lung, bone metastases, along with the extensive volume of lesions on PET/CT were identified as independent prognostic factors for disease progression in DTC patients with TENIS in the multivariate analysis. Our study revealed that presence of bone metastases was an independent prognostic indicator for the poorer survival in DTC patients with TENIS syndrome (p < 0.05). The cumulative radioiodine dose exceeding 600 mCi did not significantly impact OS, possibly due to several factors. First, in our study, only a small proportion of patients (10.9%) received a dose greater than 600 mCi. Second, the slow progression in nature of DTC may have limited the ability to observe significant outcomes within the median follow-up period. Additionally, all DTC patients with extensive [18F]FDG PET/CT findings were treated with local resection and/or systemic therapy, which could also have influenced on OS. Leonardo et al. demonstrated that only thyroglobulin > 10 ng/mL and [18F]FDG PET uptake significantly correlated with PFS. In contrast, patients with negative [18F]FDG PET/CT scans had a better PFS [32]. However, Deandreis et al. found that FDG uptake was the sole significant prognostic factor for survival [33]. The post-surgery [18F]FDG uptake status reflects the aggressive nature of lesions that have lost the ability to uptake 131I. Consequently, [18F]FDG PET/CT uptake has been linked to OS, exhibiting a stronger predictive value compared to age, sex, or metastasis status alone [34–36]. Several studies have shown the promising value of semi quantitative parameters derived from [18F]FDG PET/CT such as SUVmax, SUVmean, SUVpeak, MTV, TLG in predicting PFS and OS in DTC with TENIS syndrome [37, 38]. Nevertheless, it is essential to consider potential confounders stemming from the heterogeneity in PET/CT parameters. Therefore, the prognostic significance of [18F]FDG PET/CT in DTC remains non-generalizable and warrants cautious interpretation. This study has several limitations. Notably, histopathological or cytological confirmation of malignancy was not performed in all cases to verify the presence of malignant lesions, particullaly distant metastatic lesions. Additionally, the appropriate treatment administered to patients in positive [18F]FDG PET/CT groups may have prolonged PFS during followed-up. Finally, the small sample size in several subgroups and the follow-up time may not be sufficient to support multivariate analysis. Therefore, further multicenter studies should include larger patient cohorts, longer follow-up periods in coming times. Conclusions Qualitative [18F]FDG PET/CT is a valuable tool for stratifying DTC patients with TENIS syndrome, assisting in decision-making regarding follow-up, TSH suppression therapy, and local or systemic therapy. The negative and minimal [18F]FDG PET/CT lesion volumes showed better PFS and OS compared to those with extensive lesion volumes. The extensive [18F]FDG PET/CT lesion volumes was identified as an independent predictor of PFS in multivariate analysis. Furthermore, bone metastases were the only the independent factor predicting both PFS and OS. Acknowledgements We thank all staff in the Department of Nuclear Medicine for collecting the data and Dr. Glenn SY for technical support. Abbreviations Differentiated thyroid cancer Patients with elevated serum thyroglobulin but negative radioiodine whole-body scan Total lesion glycolysis Standard uptake value Metabolic volume Positron emission tomography Computed tomography Thyroglobulin Thyroid stimulating hormone European Association of Nuclear Medicine Progression-free survival Overall survival Positron Emission Tomography Response Criteria in Solid Tumors Response Evaluation Criteria in Solid Tumours Radioactive-iodine Authors’ contribution Basic study idea was made by M.H.S; L.N.H and N.T.P conducted patient management and procedures. Data were curated by N.T.P., analyzed by M.H.S and L.N.H, and validated by L.N.H. Draft of manuscript was written by L.N.H. and N.T.P and reviewed by all authors. M.H.S edited the manuscript. Funding No funding. Data availability Data is provided within the manuscript. Declarations Ethics approval and consent to participate The present study protocol was reviewed and approved by the Tumor Board of Hospital 108 (approval No. 338/QĐ-VNC). As the procedures involved were standard of care, the Tumor Board of Hospital 108 agreed to waive the need for written informed consent. Consent for publication NA. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement Data is provided within the manuscript.